Foundayo vs. Zepbound: Pill vs. Injection — Which Wins in 2026?

The Format Trade-Off

This comparison comes down to one question: how much weight loss are you willing to trade for the convenience of a daily pill?

When the Injection Wins

• Severe obesity (BMI ≥ 40): Higher starting weight generally benefits from the most aggressive treatment available. An 8.5 percentage point efficacy gap matters more when you have more to lose
• Dual-agonist advantage: Tirzepatide's GIP receptor activation provides metabolic benefits that a GLP-1-only drug can't match — better insulin sensitivity, potentially better fat metabolism
• You've tried a GLP-1 before without sufficient results: If semaglutide didn't produce enough weight loss, Foundayo (also a single GLP-1 agonist) may not either. Zepbound's dual mechanism offers a different approach
• Weekly dosing is easier for you: Some patients prefer one injection per week over remembering a daily pill. Adherence patterns vary by person

When the Pill Wins

• Needle phobia: It's the #1 reason people avoid GLP-1s. Foundayo eliminates the barrier entirely
• Travel: No cold chain, no sharps container, no TSA questions about syringes. Foundayo goes in your pill case
• Milder obesity (BMI 27–34): When the goal is 10–15% weight loss, Foundayo's 12.4% average gets you there. The injection's extra potency may be more than you need
• You value simplicity: Take a pill with dinner. No injection technique to learn, no site rotation, no disposal logistics

The Adherence Argument

Clinical trials measure what happens when patients take the medication perfectly. Real life is messier. Studies consistently show that oral medications have different — not necessarily worse — adherence patterns than injectables. The question isn't "which drug works better in a lab?" It's "which drug will I actually use for 12+ months?"

If the answer is "I'll never inject myself," then Foundayo at 12.4% weight loss beats Zepbound at 0% (because you didn't take it).

Can You Switch Between Them?

Yes. Lilly's ATTAIN-SWITCH trial demonstrated that patients can maintain weight loss when transitioning from injectable GLP-1 therapy to oral Foundayo. This means you could start with Zepbound for maximum initial weight loss, then transition to Foundayo for long-term maintenance — getting the best of both approaches.